Syndax Pharmaceuticals, Inc. (SNDX): Price and Financial Metrics
SNDX Price/Volume Stats
|Current price||$16.57||52-week high||$29.86|
|Prev. close||$16.65||52-week low||$11.22|
|Day high||$16.77||Avg. volume||1,086,581|
|50-day MA||$13.91||Dividend yield||N/A|
|200-day MA||$19.04||Market Cap||1.15B|
SNDX Stock Price Chart Interactive Chart >
Syndax Pharmaceuticals, Inc. (SNDX) Company Bio
Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company was founded in 2005 and is based in Waltham, Massachusetts.
SNDX Latest News Stream
|Loading, please wait...|
SNDX Latest Social Stream
View Full SNDX Social Stream
Latest SNDX News From Around the Web
Below are the latest news stories about SYNDAX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SNDX as an investment opportunity.
Syndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation at the 65th ASH Annual Meeting
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that data from the pivotal trial of revumenib, the Company's highly selective, oral menin inhibitor, will be featured in a late-breaking presentation at the 65th American Society of Hematology (ASH) Annual Meeting being held December 9-12, 2023 in San Diego, California. A copy of the abstract is now available online via the ASH website at www.he
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, November 14, 2023, at 4:45 p.m. ET.
Key Insights Using the 2 Stage Free Cash Flow to Equity, Syndax Pharmaceuticals fair value estimate is US$28.07 Syndax...
In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Click to skip past our discussion of the biotech space and straight to the 5 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Alkermes plc (NASDAQ:ALKS), Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) and ImmunoGen, Inc. […]
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on November 1, 2023 the Company granted inducement awards to purchase up to 169,600 shares of common stock to ten new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underl
SNDX Price Returns
Continue Researching SNDXHere are a few links from around the web to help you further your research on Syndax Pharmaceuticals Inc's stock as an investment opportunity:
Syndax Pharmaceuticals Inc (SNDX) Stock Price | Nasdaq
Syndax Pharmaceuticals Inc (SNDX) Stock Quote, History and News - Yahoo Finance
Syndax Pharmaceuticals Inc (SNDX) Stock Price and Basic Information | MarketWatch